Patients with AD and head & neck lesions

rated the head & neck as their most bothersome area.⁵

68% (N=199) of patients with atopic dermatitis, including head & neck lesions, rated this area as the most bothersome. Head, neck and hand lesions were the most frequently identified bothersome lesion locations among patients with AD.⁵

In head & neck patients treated with Adtralza^® for four years^7,8

Adtralza^®, known for its safety profile. With the long-term efficacy to match.

Post hoc analysis of the ECZTEND OLE trial. The 4-year cohort included patients treated with Adtralza^® for 52 weeks in ECZTRA 1 or 2, followed by 152 weeks in OLE, regardless of head & neck involvement at parent trial baseline. TCS use was optional. Data are as observed. Median head & neck EASI decreased from 3.0 at parent trial baseline to 0.2 at Year 4.^7,8 Limitation: patients assessed decreased from 1,192 at baseline to 266 at Year 4, so lost-to-follow-up and selection bias should be noted.⁸ EASI, Eczema Area and Severity Index. EASI-75, ≥75% improvement from baseline in EASI score.

ECZTRA 1 & 2 · pooled sub-analysis

EASI improvement was observed as early as Week 4.

Pooled sub-analysis of patient-reported outcomes from 1,596 randomised patients in ECZTRA 1 and 2; worst daily pruritus on an 11-point numeric rating scale (NRS). A separation was observed from Day 2 in the Adtralza^® group (n=1,196) vs placebo (n=400), P=0.001.¹¹ EASI data from a post hoc analysis of ECZTRA 3; all patients received Adtralza^® every 2 weeks (Q2W) to Week 16; last observation carried forward (LOCF) applied.⁴

Long-term safety

No new safety signals to six years.^1,2,3

Dosing schedule flexibility: Every 2 weeks - or every 4 for responders at Week 16.^1,2

Adtralza^®’s safety profile has remained consistent, with no new safety signals identified beyond the known safety profile up to 6 years in long-term studies — the ECZTEND open-label extension, in which patient numbers decreased over time from 1,639 to 84 at Year 6.^1,2,3 *Mainly reported as common cold; classified as very common (≥1/10).^1,2 Please refer to the Adtralza^® Summary of Product Characteristics (SmPC) for the full list of adverse events. At the prescriber’s discretion, every 4 weeks (Q4W) dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks with Q2W.^1,2 The probability of maintaining clear or almost clear skin may be lower with Q4W dosing.^1,2 Consideration should be given to discontinuing treatment in patients with no response after 16 weeks.^1,2 Reducing to Q4W may not be appropriate for patients >100 kg.^1,2 URTI, upper respiratory tract infection.

Given what we know now,
does Adtralza^® have a different place in your approach to treating patients like Andy?

This content is created by LEO Pharma for UK HCPs only. Adtralza^® (tralokinumab) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.^1,2
Click here for Prescribing information and adverse event reporting.
MAT-99471 September 2026.